Latest autoimmune diseases Stories
Same eczema-soothing power, with a new look FORT WORTH, Texas, Nov.
- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies
- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies EAST HANOVER, N.J., Nov.
November 14 is World Diabetes Day CHICAGO, Nov.
PARIS, November 12, 2014 /PRNewswire/ -- Collaboration to generate novel diagnostic products to support personalized therapies for
NARBERTH, Pa., Nov.
Be Joint Smart to educate roughly 48,000 local residents with PsA about their disease PORTLAND, Ore., Nov.
- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.
ReportsnReports.com adds “Bullous Pemphigoid Global Clinical Trials Review, H2, 2014” to its store.
Expert from the University of California San Francisco, regarded as one the world's leading academic centers in health sciences, will lead a discussion on pulmonary fibrosis in scleroderma.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.